Michael Wong, MD, PhD, FRPC, discusses the FDA accelerated approval of vusolimogene oderparepvec-wtpg plus nivolumab in melanoma.
Michael Wong, MD, PhD, FRPC
Advertisement
Articles by Michael Wong, MD, PhD, FRPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
4
Dr Choudhury on Understanding Mechanisms of Resistance to DLL3-Directed BiTEs in SCLC
5